US pharmaceutical company Eli Lilly threatens clinical trial funding over PBS

Millions of dollars in funding for clinical trials in Australia could be at risk if the federal government doesn't speed up approval times for drugs listed on the Pharmaceutical Benefits Scheme (PBS). According to the Australian Financial Review, United States-based pharmaceutical company is now threatening to pull that funding if the PBS approval time isn't significantly shortened. It's got the local industry looking to press the Federal Government on the need to reform the scheme as quickly as possible post-election. Guest: Liz de Somer, CEO, Medicines Australia  Producer: Grace Stranger